Free Trial

Amicus Therapeutics (FOLD) News Today

$10.53
-0.12 (-1.13%)
(As of 11:22 AM ET)
Amicus Therapeutics logo with Medical background
BNP Paribas Financial Markets Sells 334,410 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
BNP Paribas Financial Markets trimmed its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 36.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 588,635 shares of the biopharmaceutical company's stock after
Amicus Therapeutics logo with Medical background
Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell Sells 6,100 Shares
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley L. Campbell sold 6,100 shares of the company's stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at approximately $8,866,540. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Amicus Therapeutics logo with Medical background
Short Interest in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Drops By 6.5%
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) was the target of a significant decrease in short interest in June. As of June 15th, there was short interest totalling 25,800,000 shares, a decrease of 6.5% from the May 31st total of 27,590,000 shares. Based on an average daily volume of 2,560,000 shares, the days-to-cover ratio is currently 10.1 days.
Amicus Therapeutics logo with Medical background
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Moderate Buy" by Brokerages
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have issue
Amicus Therapeutics logo with Medical background
Vanguard Group Inc. Buys 1,360,613 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Vanguard Group Inc. lifted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 5.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,492,486 shares of the biopharmaceutical company's
Amicus Therapeutics logo with Medical background
83,020 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Teachers Retirement System of The State of Kentucky
Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor p
Amicus Therapeutics logo with Medical background
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stake Raised by Los Angeles Capital Management LLC
Los Angeles Capital Management LLC grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 812.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 118,360 shares of the b
Amicus Therapeutics logo with Medical background
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Wellington Management Group LLP
Wellington Management Group LLP increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 101.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,190,024 shares of the biopharmaceutical c
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Holdings Lifted by Perceptive Advisors LLC
Perceptive Advisors LLC increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,057,456 shares of the biopharmace
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Great Point Partners LLC
Great Point Partners LLC lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 49.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,280,500 shares of the biopharmaceutical company's stock after acquiring an additional
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Expected to Earn Q2 2024 Earnings of ($0.07) Per Share
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Stock analysts at Zacks Research boosted their Q2 2024 EPS estimates for shares of Amicus Therapeutics in a note issued to investors on Tuesday, June 11th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical compa
Seven Eight Capital LP Has $2 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Seven Eight Capital LP grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 313.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 140,581 shares of the
Wells Fargo & Company MN Trims Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Wells Fargo & Company MN lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 570,956 shares of the biopharmaceuti
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Rafferty Asset Management LLC
Rafferty Asset Management LLC lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 12.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 795,351 shares of the biop
Campbell & CO Investment Adviser LLC Has $2.42 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Campbell & CO Investment Adviser LLC grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 1,447.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 170,431 shares of the biopharmaceutical company's stock after purch
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Forecasted to Earn Q3 2025 Earnings of $0.05 Per Share
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Equities researchers at Zacks Research cut their Q3 2025 EPS estimates for Amicus Therapeutics in a research note issued to investors on Thursday, May 30th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical comp
UBS Group AG Acquires 303,038 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
UBS Group AG boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 58.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 824,708 shares of the biopharmaceutical company's stock after purcha
Norges Bank Acquires New Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Norges Bank acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 2,531,000 shares of the biopharmaceutical company's stock, valued at approximately
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. grew its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,268,886 shares of the biopharmaceutical company's stoc
Massachusetts Financial Services Co. MA Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Massachusetts Financial Services Co. MA increased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 32.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,415,090
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by BNP Paribas Financial Markets
BNP Paribas Financial Markets boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 138.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 923,045 shares of the biopharmaceutical company's stock after purchasing an addition
M&G Investment Management Ltd. Takes $9.95 Million Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
M&G Investment Management Ltd. acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 710,557 shares of the biopharm
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $9.04
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $9.04
Amicus Therapeutics (NASDAQ:FOLD) Upgraded by Guggenheim to "Buy"
Guggenheim upgraded Amicus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target for the company in a report on Tuesday.
Amicus Therapeutics (NASDAQ:FOLD) Issues Earnings Results
Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.04. The business had revenue of $110.40 million during the quarter, compared to the consensus estimate of $111.19 million. Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. Amicus Therapeutics's quarterly revenue was up 27.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.18) earnings per share.
Amicus Therapeutics (NASDAQ:FOLD) PT Lowered to $19.00 at UBS Group
UBS Group cut their target price on Amicus Therapeutics from $20.00 to $19.00 and set a "buy" rating for the company in a research report on Friday.
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Reaffirmed by Needham & Company LLC
Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Friday.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of "Buy" from Brokerages
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned an average recommendation of "Buy" from the three research firms that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a buy rating. The average twelve-month
Amicus Therapeutics (NASDAQ:FOLD) Sets New 52-Week Low at $9.30
Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year Low at $9.30
Amicus Therapeutics: Q1 Earnings Snapshot
Victory Capital Management Inc. Cuts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Victory Capital Management Inc. cut its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 40.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,752,687 sh
Get Amicus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

Does this make you sick? (Ad)

The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.

Get your Free Wealth Protection Kit

FOLD Media Mentions By Week

FOLD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FOLD
News Sentiment

0.00

0.88

Average
Medical
News Sentiment

FOLD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FOLD Articles
This Week

0

4

FOLD Articles
Average Week

Get Amicus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:FOLD) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners